The Economic Times daily newspaper is available online now.

    Sun Pharma names Aalok Shanghvi as whole-time director

    Synopsis

    Sun Pharma Board has appointed Aalok Shanghvi as a whole-time director for a five-year term beginning June 1, 2023. Shanghvi, the son of Sun Pharma's founder-promoter and managing director Dilip Shanghvi, has been heading key functions, including emerging markets, global generic R&D, global generic business development, and active pharmaceutical ingredient since joining the firm in 2006. The board also approved Rolf Hoffmann's appointment as an independent director for the next five years. Hoffmann has extensive experience in managing worldwide markets and creating commercial opportunities, having previously worked as an executive at Eli Lilly and Amgen.

    FILE PHOTO: The logo of Sun Pharma on the facade of its corporate office in MumbaiReuters
    Sun Pharma on Saturday said its Board has approved the appointment of Aalok Shanghvi as a whole-time director.

    Aalok Shanghvi's term as whole-time director will be effective for five years from June 1, 2023.

    Empower Your Corporate Journey with Strategic Skill Courses

    Offering CollegeCourseWebsite
    Indian School of BusinessISB Chief Technology OfficerVisit
    Indian School of BusinessISB Leadership in AIVisit
    Indian School of BusinessISB Chief Digital OfficerVisit
    Aalok Shanghvi is the son of Dilip Shanghvi, managing director and founder-promoter of Sun Pharma and is nephew of Sudhir Valia, non-executive director of the company.

    Aalok Shanghvi, who is currently heading important functions like emerging markets, global generic R&D, global generic business development and active pharmaceutical ingredient (API), joined Sun Pharma in 2006.

    He has previously handled various roles in marketing, R&D, project management, purchase and communications.

    In 2010, he headed Bangladesh and by 2014, he took over the emerging markets business, which is spread across 80 countries covering Africa, Middle East, Asia Pacific, Eastern Europe, CIS, and Latin America.

    Subsequently, he also took charge of Global Generic R&D, Global Generic Business Development and API.

    He has done his undergraduate majoring in Cellular and Molecular Biology from the University of Michigan – Ann Arbor.

    Sun Pharma Board also approved Rolf Hoffmann as an independent director for a term of five years.

    Hoffmann, is a veteran pharmaceutical industry executive with long stints at Eli Lilly and Company and Amgen in executive roles.

    "Hoffmann is a strategic and results-oriented executive who is highly respected for expertise in creating and optimizing commercial opportunities in all global markets. He has over 29 years of experience managing top 50 worldwide markets with full P&L and cross-functional accountability," Sun Pharma said in a statement to exchanges.


    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News, Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Subscribe to The Economic Times Prime and read the ET ePaper online.

    ...more

    (You can now subscribe to our Economic Times WhatsApp channel)
    (Catch all the Business News, Breaking News, Budget 2024 News, Budget 2024 Live Coverage, Events and Latest News Updates on The Economic Times.)

    Download The Economic Times News App to get Daily Market Updates & Live Business News.

    Subscribe to The Economic Times Prime and read the ET ePaper online.

    ...more
    The Economic Times

    Stories you might be interested in